CoChat
Sign Up
Cited by 266Extracellular vesicles in diseaseMultiple Myeloma Research and TreatmentsMicroRNA in disease regulation

Prognostic role of circulating exosomal miRNAs in multiple myeloma

Open access
Manier, Salomon, Liu, Chia-Jen, Avet-Loiseau, Hervé, Park, Jihye, Shi, Jiantao, Campigotto, Federico, Salem, Karma Z., Huynh, Daisy +12 more·2017·Blood
DOI 10.1182/blood-2016-09-742296PMC PMC5409448
Open this paper in CoChat — free accountOpen PDF

Abstract

Exosomes, secreted by several cell types, including cancer cells, can be isolated from the peripheral blood and have been shown to be powerful markers of disease progression in cancer. In this study, we examined the prognostic significance of circulating exosomal microRNAs (miRNAs) in multiple myeloma (MM). A cohort of 156 patients with newly diagnosed MM, uniformly treated and followed, was studied. Circulating exosomal miRNAs were isolated and used to perform a small RNA sequencing analysis on 10 samples and a quantitative reverse transcription polymerase chain reaction (qRT-PCR) array on 156 samples. We studied the relationship between miRNA levels and patient outcomes, including progression-free survival (PFS) and overall survival (OS). We identified miRNAs as the most predominant small RNAs present in exosomes isolated from the serum of patients with MM and healthy controls by small RNA sequencing of circulating exosomes. We then analyzed exosomes isolated from serum samples of 156 patients using a qRT-PCR array for 22 miRNAs. Two of these miRNAs, let-7b and miR-18a, were significantly associated with both PFS and OS in the univariate analysis and were still statistically significant after adjusting for the International Staging System and adverse cytogenetics in the multivariate analysis. Our findings support the use of circulating exosomal miRNAs to improve the identification of patients with newly diagnosed MM with poor outcomes. The results require further validation in other independent prospective MM cohorts.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2016-09-742296

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Proteasome inhibitor treatment alters miRNAs.

    “Proteasome inhibitor leads to alteration in not only the proteins but also the miRNAs (12, 13).”

    From miR-33b-3p Acts as a Tumor Suppressor by Targeting DOCK4 in Prostate Cancer (2021) · cites this paper as [12]

    The ‘Exosomal miRNAs and survival in MM’ section says serum was collected before bortezomib-and-dexamethasone therapy and analyzes baseline miRNAs as prognostic markers. The ‘Statistical analysis’ section likewise describes newly diagnosed, untreated patients. Neither passage establishes that proteasome inhibitor treatment alters miRNAs; searches for treatment-related miRNA changes found no such result in our copy. (LLM, conf=0.77)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 38

  1. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364(11):1046-1060.
  2. Chng WJ, Dispenzieri A, Chim CS, et al; International Myeloma Working Group. IMWG consensus on risk stratification in multiple myeloma. Leukemia. 2014;28(2): 269-277.
  3. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma [published correction appears in J Clin Oncol. 2005;23(25):6281]. J Clin Oncol. 2005;23(15): 3412-3420.
  4. Avet-Loiseau H, Durie BG, Cavo M, et al; International Myeloma Working Group. Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project. Leukemia. 2013;27(3): 711-717.
  5. Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised International Staging System for Multiple Myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33(26): 2863-2869.
  6. Th éry C, Zitvogel L, Amigorena S. Exosomes: composition, biogenesis and function. Nat Rev Immunol. 2002;2(8):569-579.
  7. Peinado H, Alečković M, Lavotshkin S, et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med. 2012;18(6): 883-891.
  8. Roccaro AM, Sacco A, Maiso P, et al. BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J Clin Invest. 2013;123(4):1542-1555.
  9. Melo SA, Sugimoto H, O'Connell JT, et al. Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis. Cancer Cell. 2014;26(5):707-721.
  10. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435(7043):834-838.
  11. Pichiorri F, Suh SS, Ladetto M, et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci USA. 2008;105(35):12885-12890.
  12. Guti érrez NC, Sarasquete ME, Misiewicz- Krzeminska I, et al. Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling. Leukemia. 2010;24(3): 629-637.
  13. Calin GA, Ferracin M, Cimmino A, et al. A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med. 2005;353(17):1793-1801.
  14. Yanaihara N, Caplen N, Bowman E, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 2006;9(3): 189-198.
  15. Yu SL, Chen HY, Chang GC, et al. MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell. 2008;13(1):48-57.
  16. Ueda T, Volinia S, Okumura H, et al. Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncol. 2010;11(2): 136-146.
  17. Liu N, Chen NY, Cui RX, et al. Prognostic value of a microRNA signature in nasopharyngeal carcinoma: a microRNA expression analysis. Lancet Oncol. 2012;13(6):633-641.
  18. Cortez MA, Bueso-Ramos C, Ferdin J, Lopez- Berestein G, Sood AK, Calin GA. MicroRNAs in body fluids: the mix of hormones and biomarkers. Nat Rev Clin Oncol. 2011;8(8):467-477.
  19. Durie BG, Harousseau JL, Miguel JS, et al; International Myeloma Working Group. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467-1473.
  20. Taylor DD, Zacharias W, Gercel-Taylor C. Exosome isolation for proteomic analyses and RNA profiling. Methods Mol Biol. 2011;728: 235-246.
  21. Kodani M, Yang G, Conklin LM, et al. Application of TaqMan low-density arrays for simultaneous detection of multiple respiratory pathogens. J Clin Microbiol. 2011;49(6):2175-2182.
  22. D'haene B, Mestdagh P, Hellemans J, Vandesompele J. miRNA expression profiling: from reference genes to global mean normalization. Methods Mol Biol. 2012;822: 261-272.
  23. Schwarzenbach H, Nishida N, Calin GA, Pantel K. Clinical relevance of circulating cell-free microRNAs in cancer. Nat Rev Clin Oncol. 2014; 11(3):145-156.
  24. Kubiczkova L, Kryukov F, Slaby O, et al. Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance. Haematologica. 2014;99(3):511-518.
  25. Hao M, Zang M, Wendlandt E, et al. Low serum miR-19a expression as a novel poor prognostic indicator in multiple myeloma. Int J Cancer. 2015; 136(8):1835-1844.
  26. Rocci A, Hofmeister CC, Geyer S, et al. Circulating miRNA markers show promise as new prognosticators for multiple myeloma. Leukemia. 2014;28(9):1922-1926.
  27. Huang X, Yuan T, Liang M, et al. Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer. Eur Urol. 2015;67(1):33-41.
  28. Xiang M, Zeng Y, Yang R, et al. U6 is not a suitable endogenous control for the quantification of circulating microRNAs. Biochem Biophys Res Commun. 2014;454(1):210-214.
  29. Mestdagh P, Van Vlierberghe P, De Weer A, et al. A novel and universal method for microRNA RT-qPCR data normalization. Genome Biol. 2009;10(6):R64.
  30. Cui W, Ma J, Wang Y, Biswal S. Plasma miRNA as biomarkers for assessment of total-body radiation exposure dosimetry. PLoS One. 2011; 6(8):e22988.
  31. Roush S, Slack FJ. The let-7 family of microRNAs. Trends Cell Biol. 2008;18(10): 505-516.
  32. Manier S, Powers JT, Sacco A, et al. The LIN28B/ let-7 axis is a novel therapeutic pathway in multiple myeloma [published online ahead of print 11 November 2016]. Leukemia. doi:10.1038/ leu.2016.296. · DOI
  33. Viswanathan SR, Powers JT, Einhorn W, et al. Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet. 2009;41(7):843-848.
  34. Jacobsen A, Silber J, Harinath G, Huse JT, Schultz N, Sander C. Analysis of microRNA-target interactions across diverse cancer types. Nat Struct Mol Biol. 2013;20(11):1325-1332.
  35. Spizzo R, Nicoloso MS, Croce CM, Calin GA. SnapShot: MicroRNAs in cancer. Cell. 2009; 137(3):586-586.e1.
  36. Mendell JT. miRiad roles for the miR-17-92 cluster in development and disease. Cell. 2008; 133(2):217-222.
  37. Krutilina R, Sun W, Sethuraman A, et al. MicroRNA-18a inhibits hypoxia-inducible factor 1a activity and lung metastasis in basal breast cancers. Breast Cancer Res. 2014;16(4):R78.
  38. Teng Y, Mu J, Hu X, et al. Grapefruit-derived nanovectors deliver miR-18a for treatment of liver metastasis of colon cancer by induction of M1 macrophages. Oncotarget. 2016;7(18): 25683-25697.

Cited by

Sorted by citations

Authors
Manier, S., Liu, C.-J., Avet-Loiseau, H., Park, J., Shi, J., Campigotto, F., Salem, K. Z., Huynh, D., Glavey, S. V., Rivotto, B., Sacco, A., Roccaro, A. M., Bouyssou, J., Minvielle, S., Moreau, P., Facon, T., Leleu, X., Weller, E., Trippa, L., & Ghobrial, I. M.
Affiliations
  • Harvard University (US)
  • Laboratory for Genomics in Myeloma, INSERM Unité 1037, Toulouse University Hospital, Toulouse, France;
  • Centre National de la Recherche Scientifique (FR)
  • Centre Hospitalier Universitaire de Nantes (FR)
  • Centre Hospitalier Universitaire de Lille (FR)
  • Centre Hospitalier Universitaire de Poitiers (FR)
  • Inserm (FR)
Corresponding author
  • Manier, Salomon
  • Liu, Chia-Jen
ORCID
Venue
Blood
Publisher
American Society of Hematology
Published
2017-04-27
Volume
129
Issue
17
Pages
2429-2436
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
DOI
10.1182/blood-2016-09-742296
PMC
PMC5409448
OpenAlex
W2588057136
Cited by
266
References
2
Citations by year
2026: 6 · 2025: 21 · 2024: 21 · 2023: 22 · 2022: 33 · 2021: 56 · 2020: 36 · 2019: 40 · 2018: 23 · 2017: 8
FWCI
11.96
Type
journal article
Language
en
Open access
Locations
  • Blood (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
Funders
  • National Institutes of Health
  • National Cancer Institute (R01CA154648)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
  • Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
Keywords
multiple myeloma, circulating exosomes, exosomal microRNAs, prognostic factors, let-7b, miR-18a, progression-free survival, overall survival, serum exosomes, newly diagnosed multiple myeloma
MeSH terms
Bortezomib, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Female, Humans, Karyotyping, Male, Melphalan, Middle Aged, Multiple Myeloma, Prognosis, Transplantation, Autologous, Biomarkers, Tumor, Gene Expression Regulation, Neoplastic, Survival Analysis, Case-Control Studies, Treatment Outcome, Sequence Analysis, RNA, Hematopoietic Stem Cell Transplantation, Reverse Transcriptase Polymerase Chain Reaction, MicroRNAs, Cell Line, Tumor, Exosomes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review